On the morning of October 30, Ma Xin, member of the Standing Committee of the Jiangsu Provincial Party Committee and Executive Vice Governor, performed an inspection ofJiangsu Hansoh, a subsidiary of Hansoh Pharma. Yang Xinchong, Secretary-General of the provincial government, Shen Jianrong, Director of the Jiangsu Development and Reform Commission, and Tang Libin, Director of the Jiangsu Securities Regulatory Bureau, participated in the inspection. Ma Shiguang, Secretary of the Lianyungang Municipal Party Committee, joined in the visit. Lyu Aifeng, Executive Director of Hansoh Pharma, hosted the visit and provided a brief on the company’s current innovation and development achievements.
Ma Xin (third from left) performing an inspection at Jiangsu Hansoh
Ma Xin and his delegation conducted a detailed investigation into the company's latest developments in production, operations, and innovation research. According to Lyu Aifeng, relying on an internationally leading innovative technology platform and a global R&D team of over 1,700 people, Hansoh Pharma efficiently advances its promising R&D pipeline. Currently, over 30 innovative drugs are undergoing more than 50 clinical trials. Several products have the potential to be first-in-class (FIC) or best-in-class (BIC). Seven innovative drugs that have been marketed and their corresponding nine indications are included in the national medical insurance catalog. While focusing on independent research and development, the company expedites cooperation on global innovation. It has introduced a total of 11 collaborative projects and completed two ADC product out-licensing deals. Among them, HS-20093 (B7-H3 ADC) hasbeen designated as breakthrough therapy by the FDA.
After listening to the introduction, Ma Xin affirmed the company's continuous increase in research and development investment, strengthening the breakthrough of key technologies, and promoting innovation transformation. He encouraged the company to actively explore the frontiers of global biotechnology and hasten the development and transformation of innovative technologies and products so that patients can benefit from more new drugs and good drugs.
Statements
Hansoh Pharma does not recommend the use of any unapproved drugs or indications. Medical info in this release is for informational and news reporting only, and is not for advertising purposes. Don't use it for health care or diagnosis.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as the "Hansoh Pharma"). It does not constitute a disclosure of information about the Hansoh Pharma or any investment recommendations.
The information contained in this release may include forward-looking statements related to the Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond the Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent," “project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,” “likely,” and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.
The Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither the Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.
All information in this press release is current as of the date of release. The Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, the Hansoh Pharma reserve the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
